ES2963635T3 - Vacunas de péptido PD1 humano y usos de las mismas - Google Patents

Vacunas de péptido PD1 humano y usos de las mismas Download PDF

Info

Publication number
ES2963635T3
ES2963635T3 ES18778305T ES18778305T ES2963635T3 ES 2963635 T3 ES2963635 T3 ES 2963635T3 ES 18778305 T ES18778305 T ES 18778305T ES 18778305 T ES18778305 T ES 18778305T ES 2963635 T3 ES2963635 T3 ES 2963635T3
Authority
ES
Spain
Prior art keywords
cancer
seq
peptide
cell
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18778305T
Other languages
English (en)
Spanish (es)
Inventor
Pravin T P Kaumaya
Tanios Bekaii-Saab
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mayo Foundation for Medical Education and Research
Ohio State Innovation Foundation
Mayo Clinic in Florida
Original Assignee
Mayo Foundation for Medical Education and Research
Ohio State Innovation Foundation
Mayo Clinic in Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Foundation for Medical Education and Research, Ohio State Innovation Foundation, Mayo Clinic in Florida filed Critical Mayo Foundation for Medical Education and Research
Application granted granted Critical
Publication of ES2963635T3 publication Critical patent/ES2963635T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
ES18778305T 2017-03-28 2018-03-28 Vacunas de péptido PD1 humano y usos de las mismas Active ES2963635T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762477895P 2017-03-28 2017-03-28
PCT/US2018/024831 WO2018183488A1 (en) 2017-03-28 2018-03-28 Human pd1 peptide vaccines and uses thereof

Publications (1)

Publication Number Publication Date
ES2963635T3 true ES2963635T3 (es) 2024-04-01

Family

ID=63678120

Family Applications (1)

Application Number Title Priority Date Filing Date
ES18778305T Active ES2963635T3 (es) 2017-03-28 2018-03-28 Vacunas de péptido PD1 humano y usos de las mismas

Country Status (11)

Country Link
US (1) US11684660B2 (cg-RX-API-DMAC7.html)
EP (1) EP3600398B1 (cg-RX-API-DMAC7.html)
JP (1) JP7346302B2 (cg-RX-API-DMAC7.html)
KR (1) KR102653567B1 (cg-RX-API-DMAC7.html)
CN (2) CN110636855B (cg-RX-API-DMAC7.html)
AU (2) AU2018243920B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019020386A2 (cg-RX-API-DMAC7.html)
CA (1) CA3058393A1 (cg-RX-API-DMAC7.html)
ES (1) ES2963635T3 (cg-RX-API-DMAC7.html)
RU (1) RU2019131252A (cg-RX-API-DMAC7.html)
WO (1) WO2018183488A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021512966A (ja) * 2018-02-07 2021-05-20 イミュジーン、リミテッドImugene Limited ワクチン組成物およびその使用
WO2020071869A1 (ko) * 2018-10-05 2020-04-09 알엔에이진 주식회사 표적 세포 특이적으로 결합하여 다중 면역기능이 강화된 키메라항원 및 이의용도
BR112022005044A2 (pt) 2019-09-17 2022-07-05 Ohio State Innovation Foundation Peptídeo quimérico, peptídeo sintético, composição farmacêutica, anticorpo, método de tratamento
WO2023205796A2 (en) * 2022-04-21 2023-10-26 Ohio State Innovation Foundation Human ctla-4 peptide vaccines and uses thereof
WO2024211745A1 (en) * 2023-04-05 2024-10-10 Ohio State Innovation Foundation Human pd1, pd-l1, and ctla-4 combination peptide vaccines and uses thereof
CN119019569B (zh) * 2024-08-19 2025-10-24 中国人民解放军陆军军医大学 一种可定向增强胸腺新生t细胞杀伤乳腺癌的多肽及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1601438A (cg-RX-API-DMAC7.html) 1968-10-17 1970-08-24
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US5652138A (en) 1992-09-30 1997-07-29 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus
CA2163032C (en) 1993-06-03 2001-02-06 John Landon Antibody fragments in therapy
CN1215404A (zh) * 1996-04-03 1999-04-28 佩普里瑟奇公司 非树状骨架肽载体
FR2765243B1 (fr) 1997-06-30 1999-07-30 Usinor Acier inoxydable austenoferritique a tres bas nickel et presentant un fort allongement en traction
CA2534060C (en) * 2003-07-30 2012-06-12 Vaccine Research Institute Of San Diego Hepatitis virus core proteins as vaccine platforms and methods of use thereof
GB0400440D0 (en) * 2004-01-09 2004-02-11 Isis Innovation Receptor modulators
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
EP1912680B1 (en) 2005-06-15 2014-11-26 The Ohio State University Research Foundation Her-2 peptides
NZ582823A (en) * 2007-07-27 2012-04-27 Immatics Biotechnologies Gmbh Composition of tumour-associated peptides and related anti-cancer vaccine
WO2010011315A2 (en) * 2008-07-25 2010-01-28 Viral Genetics, Inc. Proteins for use in diagnosing and treating infection and disease
US20100234283A1 (en) * 2009-02-04 2010-09-16 The Ohio State University Research Foundation Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use
US8907053B2 (en) * 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
RU2623161C2 (ru) * 2011-04-15 2017-06-22 Компуджен Лтд. Полипептиды и полинуклеотиды и их применение для лечения иммунологических нарушений и рака
EP2744830A4 (en) * 2012-06-21 2015-06-17 Compugen Ltd LSR ANTIBODIES AND USES THEREOF FOR THE TREATMENT OF CANCER
CA2884704C (en) * 2012-09-07 2023-04-04 Randolph J. Noelle Vista modulators for diagnosis and treatment of cancer
WO2014161509A1 (en) * 2013-04-05 2014-10-09 The University Of Hong Kong Novel pd1 isoforms, and uses thereof for potentiating immune responses
DK2992020T3 (da) * 2013-05-03 2020-02-10 Ohio State Innovation Foundation Cs1-specifik kimær antigenreceptor-manipulerede immuneffektorceller
TWI676636B (zh) * 2013-07-12 2019-11-11 Vlp醫療股份有限公司 包含pd-1抗原或pd-1配體抗原的類病毒粒子
TWI720946B (zh) 2014-08-08 2021-03-11 美商Vlp醫療股份有限公司 包含改質套膜蛋白質e3之類病毒粒子
EP3177640B1 (en) * 2014-08-08 2020-05-06 The Board of Trustees of the Leland Stanford Junior University High affinity pd-1 agents and methods of use
CA2971734C (en) * 2014-12-22 2025-11-18 Pd-1 Acquisition Group, Llc Anti-pd-1 antibodies

Also Published As

Publication number Publication date
US11684660B2 (en) 2023-06-27
RU2019131252A3 (cg-RX-API-DMAC7.html) 2021-06-01
KR102653567B1 (ko) 2024-04-02
EP3600398A1 (en) 2020-02-05
WO2018183488A1 (en) 2018-10-04
CN110636855A (zh) 2019-12-31
CN118909082A (zh) 2024-11-08
CN110636855B (zh) 2024-08-09
KR20190137826A (ko) 2019-12-11
AU2025201760A1 (en) 2025-05-22
JP7346302B2 (ja) 2023-09-19
AU2018243920B2 (en) 2024-12-12
RU2019131252A (ru) 2021-04-28
EP3600398B1 (en) 2023-09-13
US20200197498A1 (en) 2020-06-25
BR112019020386A2 (pt) 2020-06-09
EP3600398A4 (en) 2020-12-30
CA3058393A1 (en) 2018-10-04
AU2018243920A1 (en) 2019-10-31
JP2020512375A (ja) 2020-04-23

Similar Documents

Publication Publication Date Title
KR102653567B1 (ko) 인간 pd1 펩티드 백신 및 이의 용도
US11440964B2 (en) Method for treating a pathological condition involving the activation or proliferation of CD127 positive cells with an anti-CD127 antibody
US12589143B2 (en) Human anti-PD-L1 peptide vaccines and methods of their use
KR102776145B1 (ko) 항-bcma 폴리펩티드 및 단백질
ES2894335T5 (es) Reducción mejorada de células objetivo con bloqueo de CD47 y un agonista coestimulador inmune
JP6305920B2 (ja) 併用療法
US20190224315A1 (en) Agonist antibodies that bind human cd137 and uses thereof
RS61808B1 (sr) Antitela i polipeptidi usmereni protiv cd127
TR201816597T4 (tr) Gfr 3'e karşı insan antikorları ve bunların kullanım metotları.
CZ297633B6 (cs) Pouzití BCMA pro výrobu farmaceutického prípravkupro lécení nádoru exprimujících APRIL
KR20220069037A (ko) 항-ptcra 항체-약물 접합체 및 이의 용도
TW202426476A (zh) 用於靶向膜蛋白及貨物之內化及降解之受體介導之胞吞作用
HK40119599A (en) An isolated peptide
US20260007730A1 (en) Human ctla-4 peptide vaccines and uses thereof
WO2024211745A1 (en) Human pd1, pd-l1, and ctla-4 combination peptide vaccines and uses thereof
HK40067806A (en) Human anti-pd-l1 peptide vaccines and methods of their use
HK40013362A (en) Human pd1 peptide vaccines and uses thereof
WO2025085538A1 (en) Alarmin binding molecules and treatment of cancer
KR20250114286A (ko) 개과 악성종양에 대한 면역제